Pulmonx Corporation (LUNG) Guidance & Earnings Results
On 2026-07-29 Pulmonx Corporation reaffirmed guidance: "FY2026 revenue $90-92M, gross margin…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LUNGPulmonx CorporationFollow LUNG — free
—
Price chart with a free account
- Market cap
- 78.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 27 Oct, in 3 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 29 Jul 26 | Reaffirmed | FY2026 revenue $90-92M, gross margin ~76% · full year |
| 29 Apr 26 | Reaffirmed | FY2026 revenue $90-92M; gross margin ~75%; operating expenses $113-115M; cash burn ~$23M · full year |
| 4 Mar 26 | Lowered | FY2026 revenue $90-92M; gross margin ~75%; operating expenses $113-115M; cash decrease ~$23M · full year |
| 12 Nov 25 | — | FY2025 revenue $89-90M; gross margin ~73%; operating expenses $125-126M · full year |
| 30 Jul 25 | Lowered | FY2025 revenue $90-92M (from $96-98M); total operating expenses $128-130M (from $133-135M); gross margin ~74% · full year |
Pulmonx Corporation — questions
- What guidance did Pulmonx Corporation give?
- On 2026-07-29: "FY2026 revenue $90-92M, gross margin ~76%"
- When does Pulmonx Corporation report earnings?
- Pulmonx Corporation's next earnings report is expected on 2026-10-27.
Every figure on this page comes from Pulmonx Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.